Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H24N4O3 |
Molecular Weight | 344.4082 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1C2=C(NC(=N2)[C@H]3C[C@H]4C[C@@H]3[C@@H]5O[C@H]45)C(=O)N(CCC)C1=O
InChI
InChIKey=OQCJPFYWFGUHIN-GJKBLCTNSA-N
InChI=1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10+,11+,13-,14+/m1/s1
Molecular Formula | C18H24N4O3 |
Molecular Weight | 344.4082 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Naxifylline [CVT 124, BG 9719], a small molecule diuretic, is one of a new class of potent and highly selective adenosine A1 receptor antagonists discovered at University of Florida. Naxifylline is an A1 adenosine receptor antagonist used for the treatment of edema associated with congestive heart failure. Naxifylline appears to be one of the more potent and clearly the most A1-selective antagonist reported to date, with K1 values of 0.67 and 0.45 nM, respectively, at the rat and cloned human A1-receptors and with 1800-fold (rat) and 2400-fold (human) subtype selectivity. Naxifylline protects against the decline in renal function observed with diuretic therapy by promoting urine output.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. | 2000 Jan |
|
A(1) receptor blockade induces natriuresis with a favorable renal hemodynamic profile in SHHF/Mcc-fa(cp) rats chronically treated with salt and furosemide. | 2001 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10203354
Rats: Thereafter, rats of group 1 received a bolus injection of vehicle (Veh; 0.3 ml of a 3% solution of polyethylene glycol-400 plus 2% ethanol in 0.154 M NaCl solution), followed, at 30-min intervals, by CVT-124 at 0.1, 0.3, 0.5, and 1 mg/kg. Rats of group 2 received intravenous bolus injections of 0.3 ml of the CVT-124 vehicle, following the same course as for group 1. CVT-124 (0.1 to 1 mg/kg) caused dose-dependent increases in urine flow and fractional and absolute sodium excretion of by six- to 10-fold and, at 0.1 mg/kg, increased the GFR.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9191953
Naxifylline appears to be one of the more potent and clearly the most A1-selective antagonist reported to date, with K1 values of 0.67 and 0.45 nM, respectively, at the rat and cloned human A1-receptors and with 1800-fold (rat) and 2400-fold (human) subtype selectivity.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:57:46 GMT 2023
by
admin
on
Fri Dec 15 15:57:46 GMT 2023
|
Record UNII |
B3G45WC37L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78322
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034325
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107805
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
166374-49-8
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
B3G45WC37L
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
DB06471
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
LL-32
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
C83991
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
8152
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY | |||
|
9841075
Created by
admin on Fri Dec 15 15:57:46 GMT 2023 , Edited by admin on Fri Dec 15 15:57:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|